1. Home
  2. EXFY vs CRDL Comparison

EXFY vs CRDL Comparison

Compare EXFY & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expensify Inc.

EXFY

Expensify Inc.

HOLD

Current Price

$1.89

Market Cap

156.2M

Sector

Technology

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.01

Market Cap

132.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXFY
CRDL
Founded
2008
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
156.2M
132.6M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
EXFY
CRDL
Price
$1.89
$1.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$4.50
$8.50
AVG Volume (30 Days)
2.4M
335.7K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$142,101,000.00
N/A
Revenue This Year
$0.42
N/A
Revenue Next Year
$0.11
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.06
N/A
52 Week Low
$0.69
$0.88
52 Week High
$2.26
$1.71

Technical Indicators

Market Signals
Indicator
EXFY
CRDL
Relative Strength Index (RSI) 67.39 35.98
Support Level $1.37 $1.00
Resistance Level N/A $1.10
Average True Range (ATR) 0.16 0.05
MACD 0.02 0.00
Stochastic Oscillator 85.04 32.75

Price Performance

Historical Comparison
EXFY
CRDL

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app. Small and medium-sized businesses (SMBs) are the cornerstone of the global economy, making up almost all businesses and the majority of employment in Organization for Economic Co-operation and Development (OECD) member countries.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Share on Social Networks: